Skip to content
MIB Agents OsteoBites and osTEAo cover art

All episodes

MIB Agents OsteoBites and osTEAo, 235 episodes. Page 2 of 3.

#
Title
101

Managing Stress in AYA Cancer Patients

102

Prevention of Cisplatin-induced Hearing Loss: Implications for Young People Treated for Osteosarcoma

103

TACOS: A Phase 2 Trial of Atezolizumab and Cabozantinib in OsteoSarcoma

104

osTEAo: Making friends after a cancer diagnosis

105

Interventions to promote physical function during and after treatment for osteosarcoma

106

The Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan (CAUSAL) study

107

Developing a Multiscale Transcriptional Atlas of Sarcoma

108

Immunological Mechanisms of Cancer Defense

109

osTEAo: Long Term Osteosarcoma Survivors: Where They Were and Where They Are Now

110

Cabozantinib as a Maintenance Therapy to Prevent Recurrence of High-Risk Pediatric Solid Tumors

111

osTEAo - Coping with Cancer through Music

112

OsteoBites Preguntas & Respuestas con Nino Rainusso, MD

113

TCF-001 TRACK (Target Rare Cancer Knowledge): A Clinical Trial Studying Precision Medicine in Rare Cancers

114

Repurposing Disulfiram to Overcome Chemotherapy Resistance in Relapsed Sarcomas

115

osTEAo Tea Spill: AYA Cancer Gab Sesh

116

Addressing the Unmet Scientific Challenges in Osteosarcoma Treatment through Innovative Engineering Techniques

117

Implementing Multi-Targeted Tyrosine Kinase Inhibitors in Combination with Chemotherapy for Osteosarcoma

118

Immune Therapies in EGFR-Expressing Cancers

119

OsTEAo - An Honest Q&A with Osteosarcoma AYA Patients, Survivors, and Siblings

120

Treatment of Osteosarcoma Using Smart Targeted Drug Delivery Nanoplatforms

121

MIB Agents and SARC: A Case Study in Collaboration

122

OSI Funded Work

123

OsTEAo - Survivor's Guilt and Grief with grief coach Lori Krause

124

Pretargeted Approach to Delivery of Radiopharmaceutical Therapy for Bone Cancer - a Click Chemistry Study in Canines with Osteosarcoma

125

osTEAo - Coping with Humor: A Review of Cancer Memes

126

The Importance of Patient-Powered Osteosarcoma Research: Count Me In 

127

Osteosarcoma Organoid Models: The Potential and Limitations of Personalized Avatars

128

Reprogramming NK Cells Within the Tumor Microenvironment of Osteosarcoma Lung Metastases

129

osTEAo- Returning to Yourself: Confidence and Identity as an AYA Cancer Patient

130

OSI Connect: Osteosarcoma Answers and Assistance

131

Open Clinical Trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

132

SCF-Skp2 Protein Complex as a Therapy for Osteosarcoma by Blocking the Mutational Effects of Rb and p53

133

osTEAo - Navigating Scanxiety

134

Cold Atmospheric Plasma: A New Therapeutical Option for Osteosarcoma?

135

UHRF1 Overexpression Promotes Osteosarcoma Metastasis through Altered Exosome Production and AMPK/SEMA3E Suppression

136

Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) for Sarcoma

137

osTEAo - Navigating Campus: Limb-Salvage and Amputation Patient Perspectives

138

Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks

139

SarcoSIGHT- A Randomised Controlled Trial of Fluorescence Guided Sarcoma Surgery versus Standard Care

140

Virtual Surgical Planning and 3D Printing in Pediatric Musculoskeletal Oncological Resections

141

Two Epigenetically Distinct Cellular States in Osteo are Regulated by a State-Specific Set of Transcription Factors Driving Differential Drug Response

142

Clinical Trial: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

143

Cell Based Therapies for Osteosarcoma

144

osTEAo Q&A with Dr. Kurt Weiss - What questions do you have about Osteosarcoma but are afraid to ask?

145

Interventional Radiology/HIFU Perspectives for Osteosarcoma

146

Focal Adhesion Kinase (FAK) Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteosarcoma

147

Updates from Clinical Sequencing of 2,138 Bone and Soft Tissue Sarcomas

148

osTEAo Presents Halloween Spooky Stories

149

How Osteosarcoma Evolves from Diagnosis to Relapse

150

Transforming the Way Researchers Share Data: Lessons from the Pediatric Cancer Data Commons

151

osTEAo - Dating & Intimacy with Lauren Broschak, MSW, LCSW, OSW-C

152

Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma

153

Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

154

Inhaled Recombinant Human IL-15 in Dogs with Naturally Occurring Pulmonary Metastases from Osteosarcoma or Melanoma: a Phase 1 Study

155

Outsmarting OS 2021 Funded Research Update: Exploring Aldehyde Dehydrogenase and Androgen Receptor Actions to OutSmart Osteosarcoma Metastases

156

Back to School: OsteoWarrior and OsteoSibling Perspectives

157

Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma

158

Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma

159

COG Project: Every Child - Episode Sponsored by Osteosarcoma Institute

160

Body Image for AYAs with Cancer with Dr. Lori Weiner

161

Unanswered Clinical Questions in Sarcoma: Opportunities to Move from Bedside to Bench - Episode Sponsored by Osteosarcoma Institute

162

Molecular Profiling Identifies Targeted Therapy Opportunities in Pediatric Solid Cancer - Episode Sponsored by Osteosarcoma Institute

163

Navigating Pediatric Cancer Clinical Trials

164

Update on OSI funded phase 2 Trial of Olaparib + Ceralasertib in Recurrent Osteosarcoma

165

Limb Salvage Surgery for OS: Patient & Surgeon Perspectives sponsored by the Osteosarcoma Institute

166

"Armored" CAR T cells for Osteosarcoma sponsored by BTG Specialty Pharmaceuticals

167

Immunotherapy for Osteosarcoma - Where Do We Go From Here? Sponsored by BTG Specialty Pharmaceuticals

168

The Osteosarcoma Project sponsored by BTG Specialty Pharmaceuticals

169

osTEAo Debut

170

Update on Clinical Trial Development Targeting Tumor Microenvironment in Refractory and Metastatic Osteosarcoma

171

Exploring the Use of a Predictive Tool for Methotrexate Clearance sponsored by BTG Specialty Pharmaceuticals

172

A Phase 1/2 Study of ZN-c3 Plus Gemcitabine in Relapsed or Refractory Osteosarcoma

173

MYC Amplification as a Prognostic Biomarker in Osteosarcoma Sponsored by BTG Speciality Pharmaceuticals

174

Compassionate Use of Investigational Drugs: A Strategy to Access Unapproved Therapies for Pediatric Oncology Patients Presented by BTG Speciality Pharmaceuticals

175

The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) International Randomized Controlled Trial Sponsored by BTG Specialty Pharmaceuticals

176

Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals

177

Truths & Myths of Nutrition in Cancer sponsored by BTG Specialty Pharmaceuticals

178

Amputation for OS; Patient & Surgeon Perspectives sponsored by BTG Speciality Pharmaceuticals

179

Surgical Management of Pulmonary Metastases in People with Osteosarcoma - COG Trial

180

Human Trial for OST-HER2

181

Osteosarcoma Q&A with Dr. Peter Anderson and OsteoWarriors

182

Osteobites: Back to Activity, Rotationplasty

183

OsteoBites: Clinical Trials for Relapsed or Refractory Osteosarcoma - The OLIE Study and Beyond!

184

Encore, Testing & Research Directory

185

Real Talk: What it's really like and how WE feel about Osteosarcoma.

186

Planning for Dignity and What Matters Most to You

187

Let's Talk Fertility and Osteosarcoma

188

How "Hydroxychloroquine and "self-eating" works with Osteosarcoma.

189

Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient

190

OsteoBites Welcomes Junior Board Members to discuss "Four OsteoWarriors' Perspectives".

191

OsteoBites welcomes Dr. Moyez Jiwa to discuss "The Art of Doctoring"

192

Osteosarcoma OsteoBites S2 Ep 18: Richard Gorlick, MD & Yifei Wang, MD “Antibody Drug Conjugates for Osteosarcoma”

193

Osteosarcoma OsteoBites S2 Ep 17: Lara Davis, MD, OHSU Knight Cancer Institute “New Osteosarcoma Clinical Trials”

194

Osteosarcoma OsteoBites S2 Ep 16: Julie Lanford, MPH, RD, CSO, LDN on “Nutrition & Cancer; Truths & Myths”

195

Osteosarcoma OsteoBites S2 Ep 15: Katie Greenzang, MD, EdM Dana-Farber CI & Harvard Med School “What’s Next? Survivorship"

196

Osteosarcoma OsteoBites S2 Ep 14: Lillian Guenther, MD Dana-Farber CI & Harvard Med School “CRISPR Screening to Identify Novel Genomic Targets"

197

Osteosarcoma OsteoBites S2 E13: Scott Sauer, PhD on “Preventing Osteosarcoma Lethal Recurrence by Targeting Disseminated Tumor Cells”

198

Osteosarcoma OsteoBites S2 Ep12: Dan Prince, MD, MPH on “Regenerative Surgery for Bone Sarcomas”

199

Osteosarcoma OsteoBites S2 Ep 11: Ines Lohse, PhD on “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”

200

Osteosarcoma OsteoBites S2 Ep 10: Sumit Gupta, MD, PhD, FRCPC “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”